Corporate Presentation 1Q18. New growth cycle and value innovation
|
|
- Denis Stone
- 5 years ago
- Views:
Transcription
1 Corporate Presentation 1Q18 New growth cycle and value innovation
2 Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Sustainability 4 Strategic competitive advantages 5 Financial and Operational Performance 6 Capital Markets 2
3 Dental benefits: an incipient sector in Brazil 3 1
4 Brazil leads the global ranking of dentists Number of dentists per country (thousand) 291 ¹ 19% of the dentists in the world are located in Brazil¹ ² 63 47² 43² ² Source: FDI World Dental Federation The Oral Health Atlas 2009 ¹ Federal Council of Dentistry Brazil (October 2017) ² Eurostat
5 Brazilian dental opportunity Although 19% of world s dentists are located in the country, only 11% of brazilians covered by a dental plan 77% 11% % of the population covered by a private dental plan 14 5 Source: OdontoPrev
6 Great portion of the middle class without a dental plan Brazil s population: 200 million people 100 million people in the middle class 100 million people outside the middle class 23 million people with a dental plan 77 million people without a dental plan 6
7 Inside OdontoPrev2
8 Cost per client Cost per client Attractive cost dynamics Over time, OdontoPrev Dental Plans present a predictable Medical Plans OdontoPrev Plans Price Cost Price Cost Time Cost increases by medical inflation and better technology Short-term contract: 1 year tenor TIme Predictable cost evolution due to prevention Long-term contract: 2 year + duration 8 and more attractive cost profile than Medical Plans.
9 OdontoPrev asset light Business Model High predictability of cash flow, prepaid revenues No working capital needs Low CAPEX requirements Positive cash flow generation every day Customers Fee per user Dental care reimbursement R$ R$ Accredited dentist network 9
10 OdontoPrev: 11 years of sustainable value creation since IPO Net revenues (R$ million) 1,365 1,437 1,456 1,070 1,156 1, IPO APR17 MAR18 10
11 Revenue & membership market share: Revenue market Share (%) Membership market Share (%) ¹ Source: ANS and OdontoPrev ¹ OdontoPrev membership portfolio ex-bradesco
12 Individual plans & SME: higher growth and better returns APR17-MAR18 AVERAGE TICKET (R$ / member / month) Contribution Margin 39 Individual Plans Revenues APR17-MAR18 R$289 M (+10.6% YoY) 48% 21 SME Revenues APR17-MAR18 R$230 M (+18.2% YoY) 47% 17 Corporate Revenues APR17-MAR18 R$927 M (+0.2% YoY) 42% 12 High Low ¹ M: million NUMBER OF COMPETITORS
13 Members, revenues and contribution margin 1Q18 Members 74% 16% 10% Revenues 63% 20% 17% Contribution Margin 60% 21% 19% 1Q14 81% 12% 7% 75% 13% 13% 12% 13% 74% 13 Corporate SME Individual Plans
14 3 Sustainability
15 Sustainability The concept of Sustainability is part of OdontoPrev s culture since our foundation Since 2008, OdontoPrev has been a signatory of the United Nations Global Compact s 10 Principles Environmental Policy released in
16 Apoena Project Amalgam recycling program ECOnnomizar program Emission management Water management 16 Since 2005 Partnership with Sao Paulo University 3,100 dentists involved 18kg of recycled content Campaign to raise awareness of energy consumption at: OdontoPrev offices Accredited network of dentists Employees houses Carbon neutral program Since ,363 trees planted, an area equivalent to 13 soccer fields to offset 1,300 tons of CO2/year issued by the Company Monitor and awareness of the importance of saving water In 2016, water consumption declined 31.2 m³ against 2015, due to initiatives taken
17 Social Actions OdontoPrev seeks to offer society, especially the less privileged ones. The social interventions of OdontoPrev are related to the support of needy children of chosen communities or linked to supporting needy children and youth partner institutions. 17
18 Social actions Friends of the Future action OdontoPrev s initiative aimed at helping partner institution or creating projects focused on oral health and supporting needy children. In 2016, the Company supported 23 institutions. Assistance to low income communities - Since Free services to local residents - 18 dental offices implemented Continued care program Dental care services to needy children 6,765 children and teenagers assisted +108,000 dental procedures since
19 Our partners in Social Responsability 19
20 Strategic competitive advantages 4
21 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 21
22 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 22
23 Proprietary IT Platform: information-driven decisions 23 Complete dental record of all beneficiaries 3 decades of actuarial data Risk management and fraud prevention
24 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 24
25 Increasing online search for dental plans in Brazil Number of dental plans online search in Brazil (000 / month) Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
26 Innovation driven Company Top quality dental materials delivered door to door to the dentist free of charge + OdontoPrev online: individual plans sold at the web + Launched NEW September 1st 26
27 Wide range of unique dental care solutions Best-seller OdontoPrev online Baby tooth Well being Dental Aesthetics Dental Orto Dental VIP 27
28 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 28
29 Dental and medical plans membership evolution Million members Medical plans Dental plans , thousand thousand MAR MAR18 29 Source: ANS
30 Focused & dental only leadership since 1998 Key players, brazilian dental sector MARCH 2018 thousand members) 6,338¹ 27% market share of beneficiaries 2,033 1,588 1, , ( ) ( ) Source: ANS ¹Companies Earnings Release (Mar/18)
31 3 accelerated growth cycles, over the last decade, brings new investors to the sector 31
32 Cycle 01: Bradesco Dental (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) % 23.3% 23.9% % Source: ANS
33 Cycle 02: Amil from 2010 to 2013 (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) % 24.9% 23.8% 25.5% Source: ANS *Sold to UnitedHealthcare *
34 Negative result in Brazil since the acquisition in 2014 Net income/loss (R$ million) Source: Amil (Valor Econômico) -672
35 Cycle 03: Hapvida & Interodonto: Since 2014 (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) % 26.2% 24.5% 25.2% % ¹ APR17 MAR18¹ 2014 MAR MAR18 35 Source: ANS ¹Excludes Bradesco Dental and OdontoPrev INSS reversals
36 Dental plans sector evolution DEC14 MAR18 Thousand members +1,884 23,244 20, Others DEC14 With 14% of market share, two companies represented 38% of the growth of the sector since MAR18 36 Source: ANS
37 Quarterly net additions Thousand members JAN17 FEB17 MAR17 APR17 MAY17 JUN17 JUL17 AUG17 SEP17 OCT17 NOV17DEC17 JAN18 FEB18 37 Source: ANS -10
38 Thousand members 100 Quarterly net additions JAN17 FEB17 MAR17 APR MAY17 JUN17 JUL17 AUG17 SEP17 OCT17 NOV17 DEC JAN18 FEB Source: ANS
39 Change in control brings a new strategy of peers Thousand lives ( ) 1,550 2,132 2,003 1,846 1,946 2,000 2,033 1,550 1,588 1,286 1,197 1, ,056 1, MAR18 39 Source: ANS
40 Cross-selling dental/medical has limited upside March 2018 Players Dental (A) Medical (B) A / B 1,588 2,015 79% 1,561 2,270 69% 40 Source: ANS
41 Average ticket evolution (R$/member/month) N/A Source: ANS
42 Focus on the dental value chain PROPRIETARY CLINICS SERVICES JOINT VENTURE WITH BB SEGURIDADE PREMIUM BRAND DENTAL MATERIALS DISTRIBUTION DENTAL SOFTWARE REGIONAL BRAND NORTHEAST REGIONAL BRAND MINAS GERAIS ONLINE SCHEDULING JOINT VENTURE IN MEXICO DENTAL IMAGING DISGNOSIS 42
43 The largest bancassurance platforms in Brazil Clients + 80 million + 60 million National footprint Exclusivity 20 years 48% of branches & 52% of brazilian bank clients 43
44 Banks: strong and committed long-term partners + Back-office Price maker Product design Customer relationship Dentist network management Front-office Price takers Selling National footprint capilarity Bank branches and brokers distribution 44
45 Largest and best dentist network 28,000 dentists at 2,600 cities National distribution Differentiated academic background Continuous education 24/7 call center 45
46 OdontoPrev: 5 Financial and Operational Performance
47 Revenues R$ million 1,250 1,365 1,437 1,456 1,070 1, % APR17 MAR18 1Q17 1Q18 47
48 Revenues evolution per segment R$ million R$ million +5.4% +4.4% +19.8% % 61 20% % 15% % 63% 17% 1Q17 1Q18 1Q17 1Q18 Corporate SME Individual Plans 48
49 Incremental revenue per segment (YoY) R$ million Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 Corporate SME Individual Plans 49
50 Corporate segment quarterly revenues increase evolution +0.6% +1.2% +2.1% -0.9% -1.4% -2.3% -2.7% 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 50
51 Average Ticket per Segment (R$/member/month and YoY %) 8.2% % % Q17 1Q18 1Q17 1Q18 1Q17 1Q18 Corporate SME Individual Plans 51
52 1Q18 Net additions per segment (thousand members) Corporate SME Individual Plans 1Q18 52
53 1Q Quarterly net additions (thousand members) Q15 1Q16 1Q17 1Q18 53
54 Net additions Corporate (thousand members) Q17 1Q18 APR16- MAR17 APR17- MAR18 54
55 Net additions (thousand members) Q17 3Q17 4Q17 1Q18 APR17- MAR18 55
56 Breakdown of individual plans Thousand members +39% % 651 6% 79% 21% 98 K lives 44% 288 K lives 50% 1Q14 1Q18 Retailers 56
57 Positive effects of bank channels 1Q18 List prices & R$45.60 Retailers R$35.90 Selling expenses Profitability 10% - 15% Higher 25% - 45% Lower 57
58 Breakdown of SME members Thousand members +35% 81% % % 13% 77% 1Q14 1Q18 58
59 Quarterly and LTM Cost of Services (% of Sales) Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q¹ 3Q¹ 4Q¹ 1Q¹ Quarterly LTM 59 ¹Excludes Bradesco Dental and OdontoPrev INSS effects.
60 Pricing power offsets higher cost of services 1Q Corporate SME Individual Plans Cost of Services / member / month Average ticket 60
61 Key metrics per segment (% of Sales) Q17 1Q18 1Q171Q18 1Q171Q18 1Q17 1Q18 1Q171Q181Q17 1Q18 1Q17 1Q18 1Q17 1Q18 1Q17 1Q18 Corporate SME Individual Plans Cost of Services Selling expenses Contribution Margin 61
62 G&A (% of Sales) Personnel Others # of employees 1,587 1,560 1,588 1,581 1,460 1, ¹ 1,589 1Q18 62 ¹Excludes Bradesco Dental and OdontoPrev INSS
63 Allowance for doubtful receivables R$ million and % of Sales Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 R$ million % of Sales 63
64 Adjusted EBITDA and Adjusted EBITDA margin R$ million and % of Sales % ¹ APR17 1Q17 1Q18 MAR18¹ 64 ¹ Excludes Bradesco Dental and OdontoPrev INSS
65 Adjusted EBITDA quarterly evolution % 15.9% 1Q17 1Q18 R$ million % Sales
66 Net Income R$ million % % 34% 32% 30% 31% 18.9% ¹ APR17 1Q17 1Q18 MAR18¹ ROE 66 ¹ Excludes Bradesco Dental and OdontoPrev INSS
67 Net cash (R$ million) 508¹ 522¹ Q18 67 ¹ Includes R$121.4 million dedicated to ANS.
68 Capex: low portion of EBITDA R$ million ¹ Q17 1Q18 Adjusted EBITDA CAPEX 68 ¹ Excludes Bradesco Dental and OdontoPrev INSS
69 Cash Flow since the IPO R$ million +2, % of Sales ,0 Share buyback Capital reductions -1,617.4 Cash dividends , Net Cash DEC = Cash Generation Acquisitions Capex Shareholder Remuneratiom Stock Options² Net Cash MAR18¹ 69 ¹ Includes R$121.4 million dedicated to ANS ² Share repurchase related to the Stock Options Plan
70 Effective ta ISS (Service tax) Effective tax ISS (Service tax) 1% 3% 2% Until 2017 Jan and Feb/18 Mar/18 ISS charged and collected in Barueri Complementary Law 157/16 Average estimated tax of municipalities where the Company operates Liminal STF (Supreme Court) 70
71 Acquisition of Private dental plan operator 622K beneficiaries: 65% corporate and 35% non-corporate. #3 player in the Northeast region: ~14% market share 9x 2017 EBITDA and 2019 earn-out; In the 12 month period ended June 2017: Revenues: R$97,5 million Adjusted EBITDA: R$17,7 million Adjusted EBITDA margin: 18,1% Average ticket of ~ R$13,00 DLR ~35% 71
72 Capital Markets 6
73 Market Cap since the IPO (R$ billion, year end) IPO MAR18 73 Source: B3
74 OdontoPrev s total shareholder return since the IPO 800% 700% 600% +715% 500% 400% 300% 200% 100% 0% IBrX 158.3% ODPV3: +22.1% +30.8% -46.0% % +80.4% +8.0% +25.4% -5.2% +4.5% +0.1% +37.1% +30.4% -6.0% IBX: +6.9% +47.8% -41.8% +72.8% +2.6% -11.4% +11.5% -3.1% -2.8% -12.4% +36.7% +27.5% +11.3% 74 Source: B3
75 Global shareholder structure: investors from 34 countries MAR18 Management Treasury 1.41% 0.49% 7.6% 5.6% 6.2% 5.8% Others 3.0% 1.8% 50.01% Free Float 48.09% 19.4% 1.5% 1.2% 40.0% 1.1% 1.0% Total Capital 531,294,792 Shares 48% Free float 255,557,592 Shares 0.6% 75
76 Increasing number of shareholders Institutional and individual investors 6,480 record 5,570 4,457 3,789 4,074 MAR17 JUN17 SEP17 DEC17 MAR18 76 Source: B3
77 Corporate Governance and professional management team 77
78 Superior Corporate Governance Standards Chairman # CEO, since the 1990s Board of Directors without executive functions, 56% independent members AGM previous notice to shareholders of 30 days Disclosure of minimum, average and maximum annual compensation of executives 3 CEOs since the foundation in 1987, and 1 IRO since IPO 78
79 Key Metrics for management s compensation Quantitative goals Perception Studies Revenue EBITDA (R$) Number of members Beneficiaries Dentists HR managers Quality of services 79
80 Upcoming IR events 80 OdontoPrev s Investor Relations activities, including conference calls, webcasts, one-on-one meetings and public presentations are made by the Company s CEO and/or IRO since the 2006 IPO. Date Country Broker Event Apr 26, Q18 Webcast Apr 27, 2018 May 14, 2018 May 15, 2018 May 16, 2018 May 17-18, 2018 Jun 05-07, 2018 Jul 25, 2018 Jul 26, 2018 Jul 27, 2018 Aug 21-23, 2018 Sep 10-12, 2018 Sep 18, 2018 Oct 24, 2018 Oct 25, 2018 Oct 26, 2018 Nov 13-14, 2018 Nov 28-30, 2018 Jan 14-15, 2019 Investor Presentation - São Paulo NDR Credit Suisse - Montreal NDR Credit Suisse - Toronto NDR Bradesco - Chicago NDR Bradesco - New York BofA Merrill Lynch CALGEMs Conference - Los Angeles 2Q18 Earnings Release 2Q18 Webcast Investor Presentation - São Paulo JP Morgan 12th Healthcare Check-Up - São Paulo Morgan Stanley LatAm Conference - London UBS VII Healthcare Day - São Paulo 3Q18 Earnings Release 3Q18 Webcast Investor Presentation - São Paulo Bradesco 8th Annual CEO Forum - New York JP Morgan Brazil Opportunities Conference - São Paulo JP Morgan Global Healthcare Conference - Los Angeles
81 Your award winning Investor Relations Team José Roberto Pacheco Executive Director & IRO Roberta Carneiro IR Manager Mariana Ferraz IR Supervisor Darcio Nunciatelli IR Analyst Stella Hong IR Analyst Heriane Silva IR Intern Phone: + 55 (11) ir@odontoprev.com.br : OdontoPrevIR Corporate Headquarters Avenida Marcos Penteado de Ulhôa Rodrigues 939 Torre II / Edifício Jatobá / 14 th floor Barueri. São Paulo. Brazil Custodian & Market Maker Independent Auditors B3 Ticker 81
Corporate Presentation October New growth cycle and value innovation
Corporate Presentation October 2017 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationGrupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market. September 28th, 2012
Grupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market September 28th, 2012 All rights reserved 2012 Disclaimer This presentation may contain forward-looking statements.
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationTotal Face Group Limited
Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationAnnual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationQ Investor Kit January December 2015
Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationGN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008
GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company
More informationAstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.
[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationpwc Smoking Ban Economic Effect Analysis
pwc Smoking Ban Economic Effect Analysis November 17, 2005 Table of Contents Scope................................................................................ Methods and Conclusions................................................................
More informationLED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF
LED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF WHAT WE DO LED Medical Diagnostics Inc. provides software and imaging device solutions to Dentists, Dental Support Organizations (DSOs) & the US Military
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017
Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Table of Contents General Information and Business Activities Economic Development of
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationInvestor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free
Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationAltria Group Inc (MO-NYSE)
March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $54.00
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationBuilding a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationAttracting Talent & Driving Growth in Wisconsin
Attracting Talent & Driving Growth in Wisconsin v 2 nd Annual Future Wisconsin Economic Summit Kevin Conroy, Chairman & CEO December 9, 2015 WMC Foundation: Second Annual Future Wisconsin Economic Summit
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationSingapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More information(LO-NYSE) SUMMARY. Risk Level *
February 12, 2015 Lorillard Inc. (LO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 05/22/2012 Current Price (02/11/15) $67.55 Target Price $71.00
More information1Q2005. Hera Group presentation
1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients
More informationOperational Efficiency:
Operational Efficiency: metrics that matter Copyright Altus Ltd 214. All rights reserved. Kevin Okell Consultancy Director 15/5/214 From distribution chain to value chain Ad-valorem pricing driven from
More informationU.S. Flue-Cured Tobacco Situation & Outlook February 6, 2015
U.S. Flue-Cured Tobacco Situation & Outlook February 6, 2015 Dr. Blake Brown Hugh C. Kiger Professor Agriculture & Resource Economics College of Agriculture & Life Sciences How much are contracted pounds
More informationProdent Introduction. Welcome
Prodent Introduction Welcome 1 MEET PRODENT Over 25 years of operation in the market Over 600,000 members Over 1,700 corporate clients Over 17,000 care options Exclusive dental focus Centralized capital
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016
Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development
More informationJ.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009
J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationASX Announcement 22 June 2017
ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an
More informationAssault on Private Practice by Michael David McGuire
Assault on Private Practice by Michael David McGuire From business assaults by insurance companies... to issues related to patient treatment acceptance... to the increased cost of attracting a steady stream
More informationReynolds American to Acquire Lorillard
Reynolds American to Acquire Lorillard The Next Step in Transforming Tobacco July 15, 2014 Forward Looking Statements This presentation contains forward-looking information. Future results or events can
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationMay 6, 2008 First Quarter 2008 Results
SWEUB2227319CMDV7 May 6, 28 First Quarter 28 Results 1Q 28: Improved results in a challenging environment Page 2 Strong loan growth at 34.2% yoy Accelerated deposit growth at 31% yoy; improved loans /
More informationTelekom Austria Group Results for the First Quarter May 16, 2007
Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationWilliam Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations
William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General
More informationCorcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
More informationQUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010
QUALITAS MEDICAL GROUP LIMITED CORPORATE PRESENTATION January 2010 Contents Our Business Corporate Developments Growth Strategies Financial Highlights Summary Business Overview Who We Are Established in
More informationSirma Group Holding JSC. Consolidated financial statements for the year ending December 31, 2016
Sirma Group Holding JSC Consolidated financial statements for the year ending December 31, 216 Changes in share prices for the period ending 31.12.216 Last trading price on 3.12 1.189 BGN Change in share
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationYEAR END REPORT. September 2013 August Diamyd Medical AB (publ), Fiscal year 2013/2014
YEAR END REPORT September 2013 August 2014 Diamyd Medical AB (publ), Fiscal year 2013/2014 Reporting period, June 1, 2014 August 31, 2014 Net sales amounted to MSEK 0.2 (0,1) Loss before tax amounted to
More informationMYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017
Mental Health November 28, 2017 MYnd Analytics, Inc. OTC MYND We believe MYnd Analytics is commercializing a very valuable predictive technology in a field of medicine, mental disorders, where desicisions
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationAlignment Strategies at the JPS Health Network
Improving the Patient Experience Alignment Strategies at the JPS Health Network JPS HEALTH NETWORK 537 bed hospital, Level 1 Trauma Center Tarrant County s Safety Net Hospital 15 primary care clinics 20
More informationWELCOME TO ACTELION S AGM 2015
WELCOME TO ACTELION S AGM 2015 08 May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationConsumer Wellness in India Growth Ahead
1 Consumer Wellness in India Growth Ahead Indian Health & Wellness industry Valued at over INR 590 bn, growing at CAGR of 18% - 20% p.a. Growth expected to continue. Industry growth being driven by: Increasing
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationWoongjin Coway. 1Q 12 IR Presentation
Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This
More informationInsulin Pens - Medical Devices Pipeline Assessment, 2016
Insulin Pens - Medical Devices Pipeline Assessment, 2016 Insulin Pens - Medical Devices Pipeline Assessment, 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business and market research
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More information